Drug intelligence / Profile preview

INNO-01

Development stage: Preclinical
Lead developer: Medesis Pharma
Modality: Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

INNO-01 is a nanoparticle-formulated squalene-based emulsion developed by Medesis Pharma and licensed by Prometic. It is designed to target brain cancers and enhance the brain penetration of chemotherapeutics, particularly for glioblastoma and other central nervous system (CNS) tumors. The drug utilizes Medesis' proprietary NanoVAX platform.

Beyond the preview

Go deeper on INNO-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INNO-01.

Explore the full profile